If the risk of mass delistings is as real as some claim, with the obvious implications for patients, then surely it needs to be part of any forum hosted by or even involving the industry?
Surely the best 'patient view' is one that is fully informed?
September 2, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
AusBiotech and Tenmile partner to accelerate Australian life sciences
May 22, 2026 - - Latest News -
Industry chiefs want united front as agreement negotiations get underway
May 22, 2026 - - Latest News -
The sharper language will need to be accompanied by even sharper actions
May 22, 2026 - - Latest News -
Lundbeck Australia earns ninth consecutive 'Great Place to Work' certification
May 22, 2026 - - Latest News -
Merck funds Indigenous STEM leaders at Macquarie University
May 22, 2026 - - Latest News -
New report reveals how AI is now deciding which healthcare brands Australians see online
May 21, 2026 - - Latest News -
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 - - Latest News
